
On Tuesday evening, Ambu downgraded its financial guidance for organic growth after global shipping delays have affected sales and increased costs of its Core business in the fourth quarter of the year.
However, the CEO at the medtech company Juan José Gonzalez emphasizes that the company regards these issues as short-term, and that the focus on its most important priority hasn't shifted – which is driving growth within the visualization segment, meaning the sales of endoscopes.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app